Data analysis & interpretation
Our expertise in immuno-oncology and image analysis with several available and proprietary solutions (Digital Pathology) and our team of scientists and data analysts, guarantee comprehensive data analysis reports and interpretation with both of our unique platforms : Immunogram multimodal analysis and Atlas multimarker database.
Immunogram is a clinical research platform allowing multimodal analysis to understand the tumor microenvironment.
It integrates Immunoscore® assays, innovative technologies such as Multiplex Spatial Tissue Analysis (Brightplex®) and molecular testing in order to improve prediction of the response to therapy and personalize treatment.
Immunogram is a customizable tool enabling to picture the relevant biomarkers and phenotypes and provide a 360° view on the tumor immune contexture.
It can include several of our assays:
- Immunoscore® for T cells, T cells exhaustion and suppressor cells
- Immunosign®
- Tumor Mutational Burden
- T cell Receptor diversity
- MSI
- Key Drivers Mutations
- Integration / normalization of the biomarker landscape
All assays are amenable to clinical trial assays and companion diagnostics.
IMMUNOGRAM multimodal analysis
The Cancer Immune Atlas is a customized multimarker database in a given cancer type applying the Immunogram multimodal approach on a large number of patients’ samples.
This unique compendium of biomarkers and phenotypes provides a statistically relevant insight into the immune contexture in order to guide drug development.
Key features:
- Immunogram - based
- Build a compendium of phenotypic and molecular data for a given indication
- Enable educated decisions for portfolio management, indication extension, and combination trial design
- Sample/clinical data/ patients selected according to your objectives.
- Easy customization to include your biomarker of interest.
ATLAS multimarker database
Resources on Immunogram
#video | Aug. 2020
2’ to learn more Series: Jacques Fieschi PhD, VP, R&D, presents the R&D department and its technologies, with a focus on Brightplex®
#video | Jun. 2020
Webinar: Exploring Changes of Myeloid Cells with Chromogenic Multiplex IHC in Advanced Liver Cancer| Prof. Nagy Habibi & Jacques Fieschi, PhD
#video | May. 2020
Webinar: Capturing the Complexity of the Tumor Microenvironment | Jérôme Galon, PhD & Jacques Fieschi, PhD
#poster | Apr. 2020
Unravelling the mystery of cancer-associated fibroblasts (CAFs) populations in the tumor microenvironment by fully automated sequential chromogenic multiplex assay (AACR 2020)
#poster | Dec. 2019
Poster presented at SITC 2019
Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced Non-small cell lung cancer patients of the PIONeeR Project.
#poster | Nov. 2019
Unveiling Tumor-Associated Macrophages (TAMs) heterogeneity and plasticity by a fully automated sequential chromogenic multiplex assay (SITC 2019)
#poster | Nov. 2019
Cancer Immunogram: combining multi-parameter approach and machine learning to capture the complexity of tumor immune contexture. (SITC 2019)
#video | Nov. 2019
Webinar: Evaluating Biomarkers During Clinical Trials for Immunotherapies. A Case Study on the Pioneer Project
#video | Sep. 2019
Webinar Biomarker Evaluation for CAR T-Cell Therapy: Impact on Drug Development
#video | Apr. 2019
Immunogram Clinical Seminar (Atlanta, April 2019) | Jérôme Galon, PhD
#video | Apr. 2019
Immunogram Clinical Seminar (Atlanta, April 2019) | Jacques Fieschi, PhD
#poster | Apr. 2019
Validation of Brightplex®: a multiplex IHC solution for immune cell phenotyping of the tumor microenvironment (AACR 2019)
#poster | Apr. 2019
Poster presented at AACR 2019
Combining multimodal biomarkers as an immunogram to guide immunotherapy use: A Proof of Concept
#brochure | Mar. 2019
Brochure Clinical Research
HalioDx Biopharma Services
#poster | Nov. 2018